Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3

Author(s):  Zur Eyal

Issue:  Sep/Oct 2019 - Volume 23, Number 5
View All Articles in Issue

Page(s):  366-375

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 1
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 2
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 3
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 4
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 5
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 6
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 7
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 8
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 9
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Page 10

Download in electronic PDF format for $65

Abstract:  Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.

Related Keywords: Eyal Zur, BScPharm, RPh, MBA, cutaneous leishmaniasis, leishmania major, leishmania tropica, Israel, topical preparations, photodynamic therapy, daylight activation, photosensitizer, 5-aminolevulinic acid hydrochloride, formulations, amphotericin B liposomal gel, paromomycin sulfate liposomal gel

Related Categories: DERMATOLOGY, EXCIPIENTS, FORMULATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
Sep/Oct 2019
Pg. 366-375

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
Jul/Aug 2019
Pg. 288-293

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
May/Jun 2019
Pg. 200-207

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

PostScription: Compounding in Israel
Zur Eyal
May/Jun 2009
Pg. 262-263

Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
Sep/Oct 2019
Pg. 376-381

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Oral Mucositis: Etiology and Clinical and Pharmaceutical Management
Zur Eyal
Jan/Feb 2012
Pg. 22-33

Low-dose Pilocarpine Spray to Treat Xerostomia
Zur Eyal
Mar/Apr 2020
Pg. 104-108

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions